Virtu Financial LLC bought a new position in Genomic Health, Inc. (NASDAQ:GHDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,622 shares of the medical research company’s stock, valued at approximately $261,000.
Several other hedge funds and other institutional investors also recently modified their holdings of GHDX. Meeder Asset Management Inc. grew its holdings in shares of Genomic Health by 120.7% in the 4th quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock worth $101,000 after acquiring an additional 1,619 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Genomic Health in the 3rd quarter worth $138,000. Jane Street Group LLC acquired a new position in shares of Genomic Health in the 3rd quarter worth $227,000. Teacher Retirement System of Texas acquired a new position in shares of Genomic Health in the 4th quarter worth $242,000. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after acquiring an additional 441 shares during the last quarter. Institutional investors and hedge funds own 91.18% of the company’s stock.
Genomic Health, Inc. (NASDAQ GHDX) opened at $33.07 on Friday. Genomic Health, Inc. has a twelve month low of $26.54 and a twelve month high of $37.50. The firm has a market capitalization of $1,142.74, a price-to-earnings ratio of -300.64 and a beta of 0.61.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Thursday, March 8th. The medical research company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Genomic Health had a negative net margin of 1.13% and a negative return on equity of 0.83%. The business had revenue of $87.50 million for the quarter, compared to analysts’ expectations of $88.96 million. During the same quarter in the prior year, the firm posted $0.04 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. sell-side analysts expect that Genomic Health, Inc. will post 0.42 earnings per share for the current fiscal year.
In other Genomic Health news, insider Kimberly J. Popovits sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $34.99, for a total value of $349,900.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Phillip G. Febbo sold 5,334 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $36.99, for a total value of $197,304.66. The disclosure for this sale can be found here. Insiders have sold 48,280 shares of company stock worth $1,647,206 in the last quarter. 46.20% of the stock is currently owned by corporate insiders.
A number of brokerages recently issued reports on GHDX. Zacks Investment Research cut Genomic Health from a “hold” rating to a “strong sell” rating in a report on Friday, March 9th. Piper Jaffray Companies restated a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Thursday, March 8th. ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Canaccord Genuity reiterated a “buy” rating and set a $42.00 price target on shares of Genomic Health in a report on Tuesday, January 16th. Finally, Barclays reiterated a “sell” rating and set a $28.00 price target on shares of Genomic Health in a report on Monday, January 8th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and an average target price of $32.67.
WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/03/17/virtu-financial-llc-takes-position-in-genomic-health-inc-ghdx.html.
Genomic Health Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.